Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 19.76 USD 1.65% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Net Margin
Schrodinger Inc

-91.8%
Current
-52%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-91.8%
=
Net Income
-177.6m
/
Revenue
193.3m

Net Margin Across Competitors

Country US
Market Cap 1.4B USD
Net Margin
-92%
Country US
Market Cap 36.5B USD
Net Margin
25%
Country US
Market Cap 31.3B USD
Net Margin
10%
Country AU
Market Cap 26.1B AUD
Net Margin
50%
Country US
Market Cap 10.9B USD
Net Margin
34%
Country US
Market Cap 6.4B USD
Net Margin
-6%
Country JP
Market Cap 934B JPY
Net Margin
16%
Country US
Market Cap 5.6B USD
Net Margin
4%
Country SE
Market Cap 53.2B SEK
Net Margin
25%
Country US
Market Cap 2.4B EUR
Net Margin
-4%
Country CN
Market Cap 16.2B CNY
Net Margin
11%
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.

SDGR Intrinsic Value
15 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-91.8%
=
Net Income
-177.6m
/
Revenue
193.3m
What is the Net Margin of Schrodinger Inc?

Based on Schrodinger Inc's most recent financial statements, the company has Net Margin of -91.8%.